Opus Genetics, Inc.

Contributing Author

Recent Articles by Opus Genetics, Inc.

Jan-08	Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts IRD GlobeNewswire
Dec-16	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) IRD GlobeNewswire
Dec-11	Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference IRD GlobeNewswire
Dec-09	Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease IRD GlobeNewswire
Dec-02	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) IRD GlobeNewswire
Nov-20	Opus Genetics to Participate in Upcoming Investment Conferences IRD GlobeNewswire
Nov-13	Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease IRD GlobeNewswire
Nov-12	Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update IRD GlobeNewswire
Nov-06	Opus Genetics Announces $23 Million Registered Direct Offering IRD GlobeNewswire
Nov-06	Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retinal Disease IRD GlobeNewswire
Nov-04	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) IRD GlobeNewswire
Nov-03	Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness IRD GlobeNewswire
Oct-14	Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference IRD GlobeNewswire
Oct-02	Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025 IRD GlobeNewswire
Sep-30	Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) IRD GlobeNewswire
Sep-12	Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) IRD GlobeNewswire
Sep-04	Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions IRD GlobeNewswire
Sep-03	Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference IRD GlobeNewswire
Sep-02	Opus Genetics Appoints Rob Gagnon as Chief Financial Officer IRD GlobeNewswire
Aug-27	Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September IRD GlobeNewswire
Aug-18	Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1 IRD GlobeNewswire
Aug-13	Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update IRD GlobeNewswire
Aug-05	Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference IRD GlobeNewswire
Jul-23	Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness IRD GlobeNewswire
Jul-03	Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) IRD GlobeNewswire
Jun-26	Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia IRD GlobeNewswire
Jun-23	Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program IRD GlobeNewswire
Jun-02	Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions IRD GlobeNewswire
May-15	Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update IRD GlobeNewswire
May-12	Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May IRD GlobeNewswire
May-06	Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate IRD GlobeNewswire
May-05	Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision IRD GlobeNewswire

Opus Genetics, Inc.

Recent Articles by Opus Genetics, Inc.

Upgrade your FINVIZ experience